STRUCTURAL STUDIES OF VIRAL PROTEASES: HIV-1 PROTEASE AND HCV NS3 PROTEASE

病毒蛋白酶的结构研究：HIV-1 蛋白酶和 HCV NS3 蛋白酶

• 批准号: 8171969
• 负责人: SEEMA MITTAL
• 金额: $ 2.06万
• 依托单位: UNIVERSITY OF CHICAGO
• 依托单位国家: 美国
• 财政年份: 2010
• 资助国家: 美国
• 起止时间: 2010-08-01 至 2011-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8171969
• 关键词: Affinity; Binding; Cleaved cell; Clinical Trials; Complex; Computer Retrieval of Information on Scientific Projects Database; Disease; Drug resistance; Enzymes; Funding; Grant; HIV; HIV-1 protease; Hepatitis C; Hepatitis C virus; Institution; Legal patent; Mediating; Mutation; Peptide Hydrolases; Pharmaceutical Preparations; Population; Protease Inhibitor; Replicon; Research; Research Personnel; Resolution; Resources; Site; Source; Structure; System; United States National Institutes of Health; Variant; Viral; fitness; inhibitor/antagonist; insight; molecular recognition

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. HIV-1 protease and HCV NS3 protease are both enzymes that are required for HIV and HCV infection, respectably. Therefore, these enzymes are considered ideal targets for anti-viral drugs for the treatment of these diseases. For HIV, there are currently 9 protease inhibitors available, and several HCV NS3 protease inhibitors are currently in clinical trials. Unfortunately, drug-resistance to most of these inhibitors has been observed in replicon studies and/or treated patent populations. Our lab views drug-resistance as a change in molecular recognition such that the target enzyme retains the ability to cleave viral substrates but is no longer able to bind inhibitor. In many HIV-1 protease variants multiple site mutations co-evolve to both decrease the affinity of a particular inhibitor and increase the viability and fitness of the enzyme. Crystallographic studies of HIV-1 protease and HCV NS3 protease in complex with substrates and inhibitors will prove to be valuable in order to determine molecular interactions that mediate substrate recognition while decreasing affinity to a particular inhibitor. Structural insights gained by analyzing high resolution crystal structures of HIV-1 protease and HCV NS3 protease in complex with substrates and inhibitors will serve as a guide to develop high affinity inhibitors that are more robust against emerging drug resistant in both viral systems.

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 HIV-1蛋白酶和HCV NS 3蛋白酶分别是HIV和HCV感染所需的两种酶。因此，这些酶被认为是治疗这些疾病的抗病毒药物的理想靶标。对于HIV，目前有9种蛋白酶抑制剂可用，并且几种HCV NS 3蛋白酶抑制剂目前正在临床试验中。不幸的是，在复制子研究和/或治疗的患者群体中已经观察到对大多数这些抑制剂的耐药性。我们的实验室将耐药性视为分子识别的变化，使得靶酶保留切割病毒底物的能力，但不再能够结合抑制剂。在许多HIV-1蛋白酶变体中，多位点突变共同进化以降低特定抑制剂的亲和力并增加酶的活力和适应性。HIV-1蛋白酶和HCV NS 3蛋白酶与底物和抑制剂的复合物的晶体学研究将被证明是有价值的，以确定介导底物识别的分子相互作用，同时降低对特定抑制剂的亲和力。通过分析与底物和抑制剂复合的HIV-1蛋白酶和HCV NS 3蛋白酶的高分辨率晶体结构获得的结构见解将作为开发高亲和力抑制剂的指导，这些抑制剂对两种病毒系统中出现的耐药性更加稳健。